	US 12,440,469 B2
	P-gp inducers as protectors against chemotherapy-induced side effects, such as peripheral neuropathy (CIPN) and hair loss
Tore Bjerregaard Stage, Odense SV (DK)
Assigned to Syddansk Universitet, Odense M (DK)
Appl. No. 17/639,154
Filed by Syddansk Universitet, Odense M (DK)
PCT Filed Aug. 28, 2020, PCT No. PCT/EP2020/074042 § 371(c)(1), (2) Date Feb. 28, 2022, PCT Pub. No. WO2021/043673, PCT Pub. Date Mar. 11, 2021.
Claims priority of application No. 19194881 (EP), filed on Sep. 2, 2019.
Prior Publication US 2022/0313649 A1, Oct. 6, 2022
Int. Cl. A61K 31/337 (2006.01); A61K 9/00 (2006.01); A61K 31/475 (2006.01); A61K 31/55 (2006.01); A61K 31/57 (2006.01); A61P 17/14 (2006.01); A61P 25/02 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/337 (2013.01) [A61K 9/0014 (2013.01); A61K 31/475 (2013.01); A61K 31/55 (2013.01); A61K 31/57 (2013.01); A61P 17/14 (2018.01); A61P 25/02 (2018.01); A61P 35/00 (2018.01)]

18 Claims

1. A method of reducing chemotherapy-induced peripheral neuropathy (CIPN) in a subject in need thereof that will receive a chemotherapy, comprising:

administering a topical composition comprising a therapeutically effective amount of a P-gp inducer selected from the group consisting of rifampicin, carbamazepine or dexamethasone to the subject; and

administering a chemotherapeutic selected from the group consisting of taxanes, vinca alkaloids, epothilones, anthracyclines, proteasome inhibitors, altretamine and topoisomerase inhibitors to the subject.